Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec
Gene therapies have potential to improve outcomes of severe diseases after only a single administration. Novel therapies are continually being developed using knowledge gained from prior successes, a concept known as scientific spillover. Gene therapy advancement requires extensive development at ea...
Main Authors: | Damon Asher, Daisy Dai, Alexa C. Klimchak, Lauren E. Sedita, Katherine L. Gooch, Louise Rodino-Klapac |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-09-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S232905012300116X |
Similar Items
-
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
by: Alexa C. Klimchak, et al.
Published: (2023-12-01) -
Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
by: Jerry R. Mendell, et al.
Published: (2023-07-01) -
Absence of the dystrophin protein in Duchenne muscular dystrophy: effects on transcriptome, proteome and microRNA secretome
by: van Westering, T
Published: (2018) -
Duchenne muscular dystrophy: an historical treatment review
by: Lineu Cesar Werneck, et al. -
A rare case of dystrophinopathy: Duchenne muscular dystrophy–Becker muscular dystrophy intermediate complex
by: Rachna Gulati, et al.
Published: (2022-01-01)